Alexey Danilov
City of Hope Medical Cneter · City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexey Danilov as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:26 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04939272 · Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center · active not recruiting · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · principal investigator
- Ph2NCT04657094 · Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaCity of Hope Medical Center · active not recruiting · Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · principal investigator
- Ph1NCT03479268 · Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaCity of Hope Medical Center · completed · B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2024 to 2026 · $1,915,725 awarded in 2026Same name and institution; not confirmed by an ID
- Overcoming ibrutinib resistance in mantle cell lymphomaR01CA244576 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2021 to 2025 · $450,309 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2016 to 2026Named on NCT04939272, NCT04657094
- Cancer Center AdministrationP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mindy Roberts · fiscal years 2016 to 2026Named on NCT03479268
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:26 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Br J Clin Pharmacol · 201794 citationsRCR 3.6
- Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.J Clin Invest · 202294 citationsRCR 5.8
- 71 citationsRCR 2.3
- Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.Clin Cancer Res · 202048 citationsRCR 1.8
- Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.Br J Haematol · 202126 citationsRCR 1.3
- Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.Leuk Lymphoma · 201725 citationsRCR 0.9
- 21 citationsRCR 0.5
- Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.Leukemia · 202113 citationsRCR 0.6
- Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.Clin Lymphoma Myeloma Leuk · 202513 citationsRCR 2.9
- Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.Br J Clin Pharmacol · 202212 citationsRCR 0.9